Human CD20 Antibody - Rituximab IgG1fut Isotype

Anti-human CD20 antibody - Human IgG1fut (high effector functions)

Anti-hCD20-hIgG1fut features the variable region of rituximab and the constant region of a non-fucosylated, human IgG1 isotype. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. The binding of rituximab to CD20 results in cell destruction through different mechanisms, including direct signaling of apoptosis, complement activation, and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA to treat various lymphoid malignancies, including B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG1fut is a non-fucosylated antibody. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC) without any detectable change in complement-dependent cytotoxicity (CDC) or antigen-binding capability [1, 2].

Anti-hCD20-hIgG1fut was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells that are deficient for fucosylation and purified by affinity chromatography with protein G.

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section). InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Ofatumumab or Obinutuzumab, with either native or engineered Fc regions.

References:

1. Yamane-Ohnuki N. & Satoh M., 2009. Production of therapeutic antibodies with controlled fucosylation. corresponding MAbs. 1(3): 230–236.
2. Mizushima T., 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 16(11): 1071–1080.